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ABSTRACT
Objective To understand rates of human
papillomavirus (HPV) vaccine acceptability and factors
correlated with HPV vaccine acceptability.
Design Meta-analyses of cross-sectional studies.
Data sources We used a comprehensive search
strategy across multiple electronic databases with no
date or language restrictions to locate studies that
examined rates and/or correlates of HPV vaccine
acceptability. Search keywords included vaccine,
acceptability and all terms for HPV.
Review methods We calculated mean HPV vaccine
acceptability across studies. We conducted meta-analysis
using a random effects model on studies reporting
correlates of HPV vaccine acceptability. All studies were
assessed for risk of bias.
Results Of 301 identiﬁed studies, 29 were included.
Across 22 studies (n=8360), weighted mean HPV
vaccine acceptability=50.4 (SD 21.5) (100-point scale).
Among 16 studies (n=5048) included in meta-analyses,
perceived HPV vaccine beneﬁts, anticipatory regret,
partner thinks one should get vaccine and healthcare
provider recommendation had medium effect sizes, and
the following factors had small effect sizes on HPV
vaccine acceptability: perceived HPV vaccine
effectiveness, need for multiple shots, fear of needles,
fear of side effects, supportive/accepting social
environment, perceived risk/susceptibility to HPV,
perceived HPV severity, number of lifetime sexual
partners, having a current sex partner, non-receipt of
hepatitis B vaccine, smoking cigarettes, history of
sexually transmitted infection, HPV awareness, HPV
knowledge, cost, logistical barriers, being employed and
non-white ethnicity.
Conclusions Public health campaigns that promote
positive HPV vaccine attitudes and awareness about HPV
risk in men, and interventions to promote healthcare
provider recommendation of HPV vaccination for boys
and mitigate obstacles due to cost and logistical barriers
may support HPV vaccine acceptability for men. Future
investigations employing rigorous designs, including
intervention studies, are needed to support effective HPV
vaccine promotion among men.

Human papillomavirus (HPV) is the most common
sexually transmitted infection (STI), causing a substantial burden of disease in men and women.1 2 In
the USA, half of sexually active men and women
contract HPV at some point in their lives.1 The
prevalence of anal HPV infection is estimated at
around 15% in heterosexual men, 60% in men
who have sex with men (MSM) who are HIV negative, and 95% in HIV positive MSM.3–5
Worldwide, the majority of anal and penile
cancers among men are associated with HPV

infection.6 7 The high prevalence of anal HPV
among MSM is associated with 44 times higher
incidence of anal cancer,7 and among HIV positive
MSM approximately 60 times higher incidence of
anal cancer than that of the general population.8
Heterosexual men infected with HPV, in addition
to increasing their own risks of anal and penile
cancers, may contribute to increasing female sexual
partners’ risks of developing cervical cancer.9

HPV VACCINATION FOR MEN
The quadrivalent HPV vaccine (HPV4; Gardasil)
was licensed in the USA for men in 2009.10 In
2011 the US Advisory Committee on Immunisation
Practices approved and recommended routine use
of HPV4 for boys aged 11–21 years, with approval
for administration up to age 26 years, in order to
prevent genital warts and anal cancer.10 HPV4 is
recommended for MSM through age 26 years.
HPV4 is over 90% effective in preventing a variety
of types of HPV infection and genital warts in
young men.11 It has also demonstrated efﬁcacy
among MSM in preventing anal epithelial neoplasias that are precursors to anal cancer.12
Nevertheless, substantial debate surrounds HPV4
vaccination programmes for men.13 Based on mathematical models suggesting that male HPV4 vaccination
programmes
exceed
cost-effectiveness
thresholds,14–16 many European countries do not
include men in HPV vaccination programmes, as in
the USA, Canada and Australia,10 17 18 instead focusing on achieving expanded coverage among women
to promote herd immunity.19 Support for male
HPV4 vaccination programmes is based on evidence
of substantial clinical beneﬁts to men,20 costeffectiveness among MSM,21 largely excluded from
mathematical models, increased cost-effectiveness for
men with the addition of non-cervical outcomes to
mathematical models,15 22 23 and beneﬁts of a
gender-neutral (universal) approach to vaccination.17 22 24 Furthermore, most mathematical
models calling into question the cost-effectiveness of
male HPV4 vaccination presume 70% or greater
coverage among women,14–16 an estimate that is not
supported by data from the USA (three-dose coverage
in women ∼32%)10 and many European countries.19

HPV VACCINE ACCEPTABILITY
Vaccine acceptability is a crucial factor in uptake.23
The majority of investigations of HPV vaccine
acceptability have focused on women.25 A systematic review of six US studies focused on young
women identiﬁed HPV vaccine acceptability
ranging from 55% to 100% although meta-analysis
was not conducted and results were not disaggregated by sex.26
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A review of 23 quantitative and qualitative studies of HPV
vaccine acceptability for men reported a range of acceptability
from 33% to 78%.25 The majority of studies indicated parents
and healthcare providers (HCP) were more supportive of HPV
vaccination for women than men.25 Two review articles,22 23
one after US licensure of HPV4 for men,22 describe challenges
to achieving broad coverage and the importance of understanding vaccine acceptability for men.
In light of current US recommendations for HPV vaccination
of men,10 we conducted quantitative syntheses (meta-analyses,
weighted mean acceptability, t tests) to assess: (1) rates of HPV
vaccine acceptability and (2) factors correlated with HPV
vaccine acceptability among men.

METHODS
Eligibility criteria
We followed preferred reporting items for systematic reviews
and meta-analysis (PRISMA) guidelines.27 We included original
research studies using quantitative methods that examined rates
of HPV vaccine acceptability and/or barriers, facilitators, attitudes, sociodemographic characteristics or other factors associated with acceptability of HPV vaccines. Studies that did not
use quantitative methods, report original data, include men or
examine HPV vaccine acceptability were not included in this
analysis. Types of participants included men reporting on HPV
vaccine acceptability. We contacted corresponding authors to
provide missing and unreported data or raw data sets when
studies did not report sufﬁcient information to be included in
meta-analyses.

Outcome measures
The primary outcome was HPV vaccine acceptability rates
among men. The secondary outcomes were factors associated
with HPV vaccine acceptability: sociodemographic characteristics, HPV vaccine attitudes, HPV vaccine awareness and knowledge, HPV risk perceptions, behavioural risk, HPV vaccine
endorsements and structural factors.

Search strategy
We used a comprehensive search strategy to locate articles
meeting inclusion criteria across multiple electronic databases:
Cochrane Library, Cochrane Central Register of Controlled
Trials, AIDSLine, CINAHIL, EMBASE, PsychInfo, Social
Science Abstracts, Ovid MEDLINE, Scholars Portal, Social
Sciences Citation Index, Dissertation Abstract International,
ASSIA: Applied Social Sciences Index and Abstracts database,
Cambridge Scientiﬁc Abstracts (CSA) Sociological Abstracts,
Proquest Research Library, CSA Social Services Abstracts database and AgeLine Database. Databases were searched with no
language, geographical or time restrictions; the last search date
was 1 March 2013.

Data collection process
All titles and abstracts from the reference lists of articles were
screened for inclusion. The full article was obtained when the
ﬁrst reviewer determined the article might meet inclusion criteria based on the study objectives. Two reviewers (CHL and KA
or ND) then assessed each article for inclusion based on study
type and outcome measures, with a third reviewer (PAN) available to arbitrate in case of disagreement.

Data extraction
We developed a data extraction form using Microsoft Excel.
Two reviewers (CHL, KA or ND) extracted the following data:

article information (ie, year of publication, author, journal);
descriptive data (ie, sample size, country, participant demographics); methods and study design; and outcomes/key ﬁndings. Data regarding any variables examined as possible
correlates of HPV vaccine acceptability was sought. We developed a list of themes related to HPV vaccine acceptability based
on review of the variables explored in the included articles.

Risk of bias
We assessed risk of bias using items from the Effective Public
Health Practice Project (EPHPP) ‘Quality Assessment Tool for
Quantitative Studies’,28 which we modiﬁed for use with crosssectional studies. We assessed selection bias (representativeness
of sample, participation rate), data collection method (validity,
reliability) and study design using a rating rubric to determine if
each component had low, moderate or high risk of bias.28
Studies with no ‘high risk of bias’ ratings were considered to
have an overall low risk of bias, one ‘high risk of bias’ rating
moderate risk of bias, and more than one ‘high risk of bias’
rating a high overall risk of bias. No studies were excluded on
the basis of risk of bias.

Data analysis
For studies that quantiﬁed HPV vaccine acceptability, we linearly
transformed acceptability ratings onto a 0–100 scale. We calculated mean HPV vaccine acceptability for each study and
weighted mean acceptability overall. Subgroup analyses were
prespeciﬁed. For studies that reported participant sexual orientation we calculated weighted mean acceptability for gay/bisexual/
MSM and heterosexual men, and used unpaired t tests to
compare HPV vaccine acceptability by sexual orientation.
Meta-analysis was conducted on studies that examined similar
correlates or predictors of HPV vaccine acceptability. We used
V.2 of Comprehensive Meta-Analysis Software to calculate effect
sizes for each variable, with a random effects model to compensate for clinical and methodological diversity between studies.
We combined coefﬁcients across studies for each variable that
was examined in order to derive a global estimate of its correlation with HPV vaccine acceptability. We calculated the Q statistic to assess homogeneity of correlations across studies
(within-study variability) and the I2 index to assess the degree of
heterogeneity (between-study variability).
We included all studies examining correlates of HPV vaccine
acceptability that provided sufﬁcient data (eg, correlations, ORs,
χ2 statistics or t values) in the meta-analysis. As the majority of
studies did not evaluate interventions, we did not conduct
meta-analysis on dichotomous (intervention vs control group)
data.

RESULTS
Study selection
The literature search yielded 309 studies (see ﬁgure 1), with
100% agreement between reviewers (CHL, KA or ND) in selecting relevant articles. Of the 40 relevant studies, we excluded 9
because they were not quantitative and 2 because data were not
disaggregated by gender. Twenty-nine remaining studies were
included in this analysis.

Study characteristics
Two reviewers (CHL, KA or ND) determined whether the same
sample and study were used more than once. The 29 articles9 24 29–55 reﬂect 24 original studies,9 29 30 34–47 49–55 all
published in English. Half (n=12) of the studies were conducted
in the USA, three in Australia, two in Sweden (n=2), and one
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Figure 1 Flow diagram of articles
selection progress for human
papillomavirus vaccine acceptability
among men review.

each in Canada, Germany, the Netherlands, New Zealand,
Philippines, Singapore and South Korea. Ninety-one per cent
(n=21) of the study samples were adult men; two studies were
conducted among adolescent boys aged 14–19 years.29 43 Study
characteristics and mean HPV vaccine acceptability are outlined
in table 1.
The majority of studies (n=20; 83%) had high risk of
bias,29 34–41 43–47 49 50 52–55 three (13%) moderate risk of
bias9 30 51 and one (2%) low risk of bias.42 All studies were
cross-sectional in design except for two cohort studies.42 44
Eight studies (33%) used random sampling9 30 37 47 49–52 54;
16 studies used non-random sampling techniques.
Twenty-nine studies quantiﬁed HPV vaccine acceptability
among men (see table 1). We included 22 studies
(n=8360)9 24 29 30 34–47 49 51 53–55 in the calculation of mean
HPV vaccine acceptability because in several cases9 24 30–33 41 48 51
different studies were based on the same sample. In one study we
treated two samples separately as the authors reported separate
means and correlates for men enrolled in a clinical study and
college students.30 31 Among these 22 investigations, mean HPV
vaccine acceptability ranged from 8.2 to 94.0 with overall mean
acceptability of 56.6 (SD 21.3) (weighted mean=50.4, SD 21.5).
In the nine studies that reported HPV vaccine acceptability
and sexual orientation, weighted mean acceptability was 58.44
(SD 16.76) among gay/bisexual/MSM (n=986) and 50.98 (SD
19.67) among heterosexuals (n=1713),9 35 41 42 44 51 53–55
although not statistically signiﬁcant (t (2699)=0.24, p=0.81).

Meta-analytic results: correlates of HPV vaccine
acceptability among men
Sufﬁcient data were provided to examine the association
between HPV vaccine acceptability and factors in seven categories: sociodemographics, HPV knowledge, HPV risk perceptions,
HPV vaccine attitudes, endorsement from others, behavioural
risk indicators and structural barriers. Table 2 reports weighted
mean correlational effect sizes measuring the association of each
factor with HPV vaccine acceptability and 95% CIs, as well as
the Q test of homogeneity and I2 index of between-study variability. I2 values of 25% represent low, 50% medium and 75%
high heterogeneity.56 Sixteen studies (n=5048) were included in
the meta-analysis.9 24 30 34–37 40 42 44–56
570

We used a random effects model in the meta-analysis to account
for between-study variability. As the small number of studies examining many factors precluded subanalyses of moderator variables
or meta-regression, we examined individual results to identify
potential reasons for between-study variability. Substantive (ie, participant characteristics) and methodological (ie, sample size) differences may have impacted between-study variability.
We identiﬁed factors associated with HPV vaccine acceptability across seven domains.
HPV vaccine attitudes: acceptability was positively correlated
with perceived HPV vaccine beneﬁts (r=0.51, p<0.001), anticipatory regret (r=0.27, p<0.001), perceived HPV vaccine effectiveness
(r=0.19, p<0.001); and negatively correlated with fear of needles
(r=−0.11, p<0.05) and fear of side effects (r=−0.09, p<0.01).
HPV vaccine endorsement: acceptability was positively correlated with HCP recommendation (r=0.42, p<0.01), supportive/
accepting social environment for HPV vaccines (r=0.18,
p<0.001) and negatively correlated with partner thinks one
should get the vaccine (r=−0.41, p<0.001).
HPV risk perceptions: perceived risk or perceived susceptibility to HPV infection (r=0.25, p<0.001) and perceived HPV
severity (r=0.09, p<0.001) were positively associated with
acceptability.
Behavioural risk indicators: number of lifetime sexual partners (r=0.18, p<0.01), having a current sex partner (r=0.17,
p<0.05), smoking cigarettes (r=0.12, p<0.05) and history of
STI (r=0.10, p<0.05) were positively correlated with HPV
vaccine acceptability. Non-receipt of hepatitis B vaccine was
negatively correlated with acceptability (r=−0.16, p<0.001).
HPV awareness (ie, having heard about HPV) (r=0.17,
p<0.01) and HPV knowledge (ie, correctly answering questions
about HPV) (r=0.09, p<0.05) were positively associated with
acceptability.
Structural barriers: vaccine cost (r=−0.17, p<0.001), logistical barriers (eg, hassle, time, transportation) (r=−0.16,
p<0.05) and need for multiple shots/doses (r=−16, p<0.01)
were negatively correlated with HPV vaccine acceptability.
Sociodemographic characteristics: being employed (r=0.13,
p<0.05) and non-white (vs white) ethnicity (r=0.09, p<0.05)
were positively associated with HPV vaccine acceptability.
Educational level, included in the majority of studies examined,
approached signiﬁcance (r=0.08, p=0.05).
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Table 1 Studies addressing human papillomavirus (HPV) vaccine acceptability, study characteristics and risk of bias, ordered by mean vaccine
acceptability (n=29)*
HPV vaccine
acceptability mean†

Author(s)

Population

Age (range,
mean)

Sexual orientation/behaviour‡
(%)

94.0
93.6§
77.5

Rand et al29
Daley et al30; Daley et al31
Jones et al45

Adolescents
Adults
College
students
Adolescents
Adults

15–17, M=N/R
18–70, M=27.8
18–32, M=N/R

N/R
N/R
N/R

74.3
74.0

71.5¶

Gottvall et al43
Gilbert et al32; Gilbert
et al33; McRee et al48;
Reiter et al51
Hernandez et al44

14–19, M=16.0
18–59, M=N/R

Adults

18–79, M=N/R

70.8
68.8

Petrovic et al35
Bynum et al38

Adults
College
students

18–26, M=22.3
N/R, M=20.6

65.8

Chelimo et al39

65.5

Gerend et al42

64.4
62.0

Thomas et al55
Daley et al30; Daley et al31

55.4
48.0

Oh et al49
Lenselink et al46

47.3
47.0

Marshall et al47
Simatherai et al53

College
students
College
students
Adults
College
students
Adults
College
students
Adults
Adults

45.3

Crosby et al40

College
students

37.0

Heterosexual
men

18–59, M=N/R

36.0
34.3††
33.0

Reiter et al9; Gilbert et al32;
Gilbert et al33; McRee
et al48
Wheldon et al34
Sundstrom et al54
Ferris et al24; Ferris et al41

Adults
Adults
Adults

18–29, M=21.6
18–30, M=23**
18–45, M=N/R

28.9††
8.2

Young et al36
Blodt et al37

18–31, M=21.2
18–25, M=N/R

N/R
N/R

Pitts et al50
Sauvageau et al52

Adults
Vocational
students
Adults
Adults

Gay/bisexual
MSM, heterosexual
Heterosexual (95.4%), Gay/bisexual
(4.6%)
N/R
N/R

18–54, M=34.8
18–69, M=44.8

N/R
N/R

Sample
size

Country

Risk of
Bias

22
296
138

USA
USA
USA

High
High
High

N/R
Gay/bisexual

608
306

Sweden
USA

High
Moderate

445

USA

High

121
575

Australia
USA

High
High

N/R, M=19.8

MSM (20.0%); heterosexual
(80.0%)
N/R
Heterosexual (91.1%); Gay/
bisexual/unsure (4.5%); Unknown
(4.5%)
N/R

38

High

18–24, M=18.8

Heterosexual

356

New
Zealand
USA

Low

22–56, M=36.6
18–22, M=N/R

MSM
N/R

191
198

USA
USA

High
High

N/R, M=53.1**
18–25, M=19.8

N/R
N/R

496
223

South Korea
Netherlands

High
High

N/R, M=N/R
19–71,
M=27.0**
18–24, M=20.2

N/R
MSM (100.0%)

852
200

Australia
Australia

High
High

History of same-sex experience
(6.1%); No same-sex experience
(93.9%)
Heterosexual

148

USA

High

297

USA

Moderate

USA
Sweden
USA

High
High
High

143
245

Philippines
Germany

High
High

930
154

Singapore
Canada

High
High

179
1712
571

Mean acceptability 56.64 (SD 21.32; median=62.0; SEM 4.45; 95% CI 47.42 to 65.86); N=8360 (22 studies); Range: 8.2–94.0.
Weighted mean acceptability: 50.43 (SD 21.49).
*Twenty-three unique samples were included in calculation of overall mean acceptability.
†Acceptability on a 0–100 point scale.
‡Mean acceptability across race/ethnicity.
§Sexual orientation or behaviour, as reported by authors.
¶Mean acceptability across sexual orientation.
**Median.
††Mean acceptability for vaccines with different costs.
MSM, men who have sex with men; N/R, Not reported.

Perceived HPV vaccine beneﬁts, anticipatory regret, HCP recommendation and partner thinks one should get vaccine had
medium effect sizes on HPV vaccine acceptability (see table 2),
based on Cohen’s classiﬁcation.57 The remaining correlates had
low effect sizes.

DISCUSSION
This meta-analysis reveals a moderate level of HPV vaccine
acceptability among men (50.4 on a 100-point scale) across 22

studies totalling 8360 participants, with a wide range of acceptability (8.2–94.0) across studies. In contrast, acceptability was
considerably higher (55.0–100.0) in a review of US studies
focused on young women,26 although mean acceptability was
not reported.
Meta-analysis results across 16 studies (n=5048) indicate
the inﬂuence of positive HPV vaccine attitudes, HCP recommendation, perceived HPV risk and HPV awareness and
knowledge on HPV vaccine acceptability for men. Health
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Table 2 Meta-analysis of correlates of human papillomavirus (HPV) vaccine acceptability among men (n=16)9
Theme

Factor

Number of studies

Effect size

HPV vaccine attitudes

Perceived HPV vaccine benefits

335

Anticipatory regret if not
vaccinated
Perceived HPV vaccine
effectiveness
Fear of needles

29

0.51 (0.31, 0.66),
p<0.001
0.27 (0.21, 0.32),
p<0.001
0.19 (0.12, 0.26),
p<0.001
−0.11 (−0.21, −0.00),
p<0.05
−0.09 (−0.14, −0.04),
p<0.01
0.42 (0.13, 0.64),
p<0.01
−0.41 (−0.51, −0.31),
p<0.001
0.18 (0.08, 0.27),
p<0.001
0.25 (0.15, 0.34),
p<0.001
0.09 (0.03, 0.16),
p<0.001
0.18 (0.09, 0.28),
p<0.01
0.17 (0.04, 0.30),
p<0.05
−0.16 (−0.02, −0.08),
p<0.001
0.12 (0.02, 0.22),
p<0.05
0.10 (0.01, 0.18),
p<0.05
0.17 (0.05, 0.30),
p<0.01
0.09 (0.01, 0.16),
p<0.05
−0.17 (−0.25, −0.07),
p<0.001
−0.16 (−0.32, −0.00),
p<0.05
−0.16 (−0.27, −0.05),
p<0.01
0.13 (0.03, 0.22),
p<0.05
0.09 (0.03, 0.15),
p<0.01
0.08 (−0.00, 0.16),
p=0.054

HPV vaccine endorsements

HPV risk perceptions

Behavioural risk indicators

HPV education

Structural barriers

Socio-demographic
characteristics

42 52

51

9 31 37 42 44 51

6

430

31 36 40

24 30 35–37 40 44

Fear of side effects

7

HCP recommended HPV
vaccine
Partner thinks should get
vaccine
Supportive/accepting social
environment
Perceived HPV risk/
susceptibility
Perceived HPV severity

59

24 30 31 51

224

44

30 35 36 44

4

109
79

31 35–37 40 42 45 49 51

30 35 40 42 49 51

637

42 44–46 52

Number of lifetime sexual
partners
Have a current/recent sex
partner
Did not receive hepatitis B
vaccine
Smokes cigarettes

4

History of STI

430

40 44 51

HPV awareness

424

42 46 51

24 35 36 40 42 46

6

29

51

9 24 44 51

9 30 31 34 35 42 45 46 50 51

HPV knowledge

10

Cost

730

Logistical barriers (hassle,
time)
Need for multiple shots

69

Employed

39

36 51

Non-white ethnicity

89

30 31 35 42 44 45 51

Education

31 35 36 40–42

30 36 42 44 51

30 31

2

9 30 31 35–37 44 49 51

9

24 30 34–37 40 42 44–56

Homogeneity
index, Q

Between-study
variability, I2

6.03, p<0.05

83.42

0.59, p=0.44

0.00

12.01, p<0.05

58.36

2.38, p=0.49

0.00

3.95, p=0.56

0.00

50.84, p<0.01

92.13

1.62, p=0.20

38.32

4.82, p=0.19

37.65

40.99, p<0.01

78.05

11.05, p=0.09

45.73

11.95, p<0.05

58.16

25.72, p<0.01

80.56

1.02, p=0.31

2.84

7.06, p=0.07

57.50

2.99, p=0.39

0.00

8.83, p<0.05

66.02

37.84, p<0.01

76.22

31.94, p<0.01

81.22

49.20, p<0.01

89.84

0.23, p=0.89

0.00

0.49, p=0.78

0.00

6.86, p=0.44

0.00

15.95, p<0.05

49.86

HCP, healthcare providers; STI, sexually transmitted infection.

promotion messaging that fosters positive attitudes about
HPV vaccination beneﬁts for men, accurate HPV risk perceptions, and that enhances awareness and knowledge regarding
HPV may increase the acceptability of HPV vaccination for
men.
We found no signiﬁcant difference in HPV vaccine acceptability between gay, bisexual and other MSM, who would beneﬁt
most from HPV4 vaccination,7 8 and heterosexual men. Results
from the meta-analysis suggest that in addition to promoting
HPV4 vaccination for all boys and young men,23 25 48 51 targeted messaging for young MSM to support perceived HPV
vaccine beneﬁts and effectiveness, and accurate perceptions of
HPV risk may increase acceptability.
HCP recommendation, the correlate with the second highest
impact on HPV vaccine acceptability after perceived HPV vaccine
beneﬁts, has been identiﬁed as an important factor in HPV vaccine
572

acceptability for girls,26 and patient acceptance of hepatitis B vaccines.58 HCP-identiﬁed barriers to hepatitis B vaccination—lack of
government reimbursement, patient non-disclosure of risk and
inadequate time to assess risk59—suggest that in addition to promoting HCP recommendation of HPV4 vaccination for boys, it is
important to assess systemic and structural barriers that may
impede HCP recommendation.
The impact of HPV risk perceptions, awareness and knowledge on HPV vaccine acceptability is notable given evidence of
low levels of HPV knowledge and awareness among
men.32 50 60 Mechanisms to foster accurate HPV risk perceptions and awareness might involve addressing the prevalence of
HPV infection and its association with cancers among men,
highlighting cancer prevention as a beneﬁt of HPV vaccination
for boys48 and challenging false beliefs that HPV vaccines are
not relevant for men.25
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Notably, out-of-pocket cost, as reported in earlier
reviews,22 23 25 logistical barriers and the need for a series of
injections were negatively associated with acceptability. In
meta-analysis these structural barriers had a greater impact than
HPV vaccine knowledge (the most often studied correlate)
and effect sizes equal to behavioural risk factors. In addition to
tailored educational interventions government ﬁnancing of
HPV4 vaccination, and interventions to reduce barriers in access
to vaccination may signiﬁcantly increase HPV4 vaccine acceptance among men.
Finally, further research is needed to explore the negative
association between partner thinks one should get the HPV
vaccine and HPV vaccine acceptability, based on only two
studies.24 44 Partner endorsement might implicate stigma and
the association of HPV as a women’s disease.25
Limitations to this meta-analysis include the absence of intervention studies, the relatively small number of studies and exclusion of unpublished studies, with few studies from each of
several countries outside the USA. The lack of intervention
studies precludes using RevMan 5 for meta-analyses; and some
correlates of HPV vaccine acceptability are based on few
studies. The limited number of studies in each setting precludes
subanalysis by country. Additional studies overall and within
each setting will help to identify possible differences in acceptability, including by healthcare systems and culture. Two studies
of parental acceptance of HPV vaccines for male adolescents
were included in the calculation of mean acceptability though
not included in meta-analysis; given different challenges to
uptake for adolescents and adults, meta-analysis of parental
acceptance of HPV vaccination for boys is indicated.
Another limitation is due to the high risk of bias among the
majority of studies included in the meta-analysis; this is indicative of weak study designs (ie, cross-sectional, non-random
sampling) and suggests caution in generalising the results.
However we used a random effects model that takes into
account between-study and within-study variability, which suggests that the effect sizes approximate an appropriate mean of
a distribution of effects. This meta-analysis provides a quantitative synthesis of the literature, indicating correlates of HPV
vaccine acceptability and the magnitude and direction of these
associations among a large sample of men across different
studies.
Finally, as most of the studies reviewed were conducted
before the US Advisory Committee on Immunisation Practices
recommended routine HPV4 vaccination of men, levels and
correlates of HPV vaccine acceptability may shift with additional
post-2011 studies. However, low HPV vaccine coverage among
young women in the USA and Europe since licensure in
200610 18 suggests the importance of synthesising available
evidence on acceptability to guide evolving policy
recommendations.
This meta-analysis suggests the importance of future investigations using more rigorous designs, including intervention
research, to address factors that promote HPV vaccine acceptability among men. Generally lower levels of support for HPV
vaccination among HCP and parents for young boys versus
young girls11 25 and the particular need for HPV4 vaccination
in gay/bisexual/MSM, indicate the importance of routinely disaggregating data by sex and sexual orientation in future investigations of HPV vaccine acceptability.
Overall, the moderate level of vaccine acceptability among
men in the case of HPV, the most common STI, supports the
need for evidence-informed interventions to address widespread
gaps between HPV vaccine recommendations and actual use.

Key messages
▸ A moderate level of human papillomavirus (HPV) vaccine
acceptability (50.4 on a 100-point scale) was reported
among 8360 men across 22 studies.
▸ Perceived HPV vaccine beneﬁts and healthcare provider
recommendation were the two most inﬂuential correlates of
HPV vaccine acceptability among men.
▸ HPV vaccine cost and logistical barriers may pose signiﬁcant
obstacles to uptake.
▸ HPV vaccination campaigns targeting men should promote
awareness of HPV, HPV-associated cancer risks and HPV
vaccine efﬁcacy, and healthcare providers’ recommendation
of HPV vaccination for boys.
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